For the Inventor, By the Inventor

Enter assignee name

Thousand Oaks, CA, United States of America

Onyx Therapeutics, Inc.

USPTO Granted Patents = 50

CIPO Patents = 6

EPO Patents = 24

Forward Citations = 633

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Guy J Laidig (25 out of 31 patents)

Mark Stephen Smyth (17 out of 39 patents)

Kevin D Shenk (16 out of 27 patents)

4. Han-Jie Zhou (14 out of 37 patents)

5. Mark K Bennett (14 out of 35 patents)

6. Pasit Phiasivongsa (12 out of 26 patents)

7. Francesco Parlati (11 out of 21 patents)

8. Catherine Sylvain (9 out of 65 patents)

9. Christopher J Kirk (7 out of 8 patents)

10. Louis C Sehl (7 out of 15 patents)

11. Henry Johnson (5 out of 12 patents)

12. David C Moebius (5 out of 11 patents)

13. Congcong M Sun (5 out of 6 patents)

14. Dustin L McMinn (5 out of 31 patents)

15. Shabbir T Anik (4 out of 7 patents)

Core Competencies:

Protease Inhibitors

Peptide Epoxyketones

Immunoproteasome Inhibitors

Prodrugs

Combination Therapy

Cyclodextrin Complexation

Liposomal Compositions

Modified Release Formulations

Enzyme Inhibition

Metastasis Suppression

Crystalline Compounds

50 patents: Sort by Forward Citations

1. 11078233 - Tripeptide epoxy ketone protease inhibitors (2021-08-03),

2. 10870889 - Immunoglobulin expression levels as biomarker for proteasome inhibitor response (2020-12-22),

3. 10682419 - Prodrugs of peptide epoxy ketone protease inhibitors (2020-06-16),

4. 10647744 - Tripeptide epoxy ketone protease inhibitors (2020-05-12),

5. RE47954 - Combination therapy with peptide epoxyketones (2020-04-20),

6. 10596222 - Combination therapy with peptide epoxyketones (2020-03-24),

7. RE47302 - Peptide epoxyketone immunoproteasome inhibitors (2019-03-18),

8. 10159746 - Cyclodextrin complexation methods for formulating peptide proteasome inhibitors (2018-12-25),

9. 10150794 - Compounds for enzyme inhibition (2018-12-11),

10. 10022326 - Liposomal compositions of epoxyketone-based proteasome inhibitors (2018-07-17),

11. 9878047 - Prodrugs of peptide epoxy ketone protease inhibitors (2018-01-30),

12. 9657058 - Compounds for enzyme inhibition (2017-05-23),

13. 9657057 - Dipeptide and tripeptide epoxy ketone protease inhibitors (2017-05-23),

14. 9511109 - Combination therapy with peptide epoxyketones (2016-12-06),

15. 9434761 - Tripeptide epoxy ketone protease inhibitors (2016-09-06),

Onyx Therapeutics, Inc. is a biotechnology company dedicated to developing innovative gene therapies for rare diseases. With a focus on delivering transformative treatments, Onyx aims to improve the lives of patients with limited or no treatment options. By leveraging advanced technologies and scientific expertise, Onyx is actively engaged in research, development, and clinical trials to bring potential therapies to those in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

50 Patents

#10 in Thousand Oaks, CA

#1,607 in California

#6,769 in US

#13,590 in the World

Thousand Oaks, CA, United States of America

Onyx Therapeutics, Inc.

Forward Citations = 633

49 inventors:

Guy J Laidig (25 out of 31 patents)

Mark Stephen Smyth (17 out of 39 patents)

Kevin D Shenk (16 out of 27 patents)

4. Han-Jie Zhou (14 out of 37 patents)

5. Mark K Bennett (14 out of 35 patents)

Please report any incorrect information to support@idiyas.com

Loading…